UCB announced new data from the evaluation of BIMZELX (bimekizumab) at the 2026 American Academy of Dermatology (ADD) Annual Meeting in Denver, US. 

The data assesses BIMZELX’s ability to provide on-treatment remission, as defined by the National Psoriasis Foundation (NPF), and complete skin clearance up to four years with retreatment after stopping treatment. 

Data from a post hoc analysis of the first year of the BE RADIANT and BE VIVID trials showed 62.6% and 64.9% of PSO patients treated with bimekizumab achieved NPF-defined on-treatment remission during any =six-month period.

At the earliest time point at which remission could be observed across both trials, week 28, 10.4% and 12.4% of patients receiving the treatment in the BE RADIANT and BE VIVID trials, respectively, achieved NPF-defined remission. 

April Armstrong, Professor and Chief of Dermatology at the University of California, Los Angeles (UCLA), US, said: “The recent National Psoriasis Foundation definition of on-treatment remission provides clinicians with a benchmark in routine practice, helping them feel confident that those living with psoriasis can reach and maintain minimal or no disease.”

UCB presented a total of eleven abstracts, from across the bimekizumab portfolio in psoriasis, hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis, at the 2026 ADD Annual Meeting. 

Affecting around 125 million people worldwide, psoriasis is a chronic inflammatory disease that can cause red patches of skin covered with silvery-white scales and dry cracked skin that may bleed. 

Donatello Crocetta, Chief Medical Officer, UCB, said: “Achieving sustained inflammation control and complete skin clearance is our goal for people living with psoriasis, and generating the evidence to support that progress is fundamental to advancing care.

“At the same time, continuity of treatment may not always be possible in real-world clinical practice. These findings show high response rates following retreatment with bimekizumab and indicate potential to re-establish disease control without meaningfully impacting long-term outcomes.”